Evidence map›Paper›PMID 26563094›Full record

ReviewEuropean journal of neurology2016

Disease-modifying treatments for multiple sclerosis - a review of approved medications.

Ø Torkildsen, K-M Myhr, L Bø

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Dietary interventions for multiple sclerosis-related outcomes.The Cochrane database of systematic reviews · 2020
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Association of medication adherence with treatment preferences: incentivizing truthful self-reporting.The European journal of health economics : HEPAC : health economics in prevention and care · 2025
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Observational
  18. Review
  19. In-Depth Characterization of L1CAMInternational journal of molecular sciences · 2025
    Article
  20. Article

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ø TorkildsenDepartment of Clinical Medicine, KG Jebsen MS Research Centre, University of Bergen, Bergen, Norway.
K-M MyhrDepartment of Clinical Medicine, KG Jebsen MS Research Centre, University of Bergen, Bergen, Norway.
L BøDepartment of Clinical Medicine, KG Jebsen MS Research Centre, University of Bergen, Bergen, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThere is still no curative treatment for multiple sclerosis (MS), but during the last 20 years eight different disease-modifying compounds have been approved for relapsing-remitting MS (RRMS).

methodsA literature search was conducted on published randomized controlled phase III trials indexed in PubMed on the approved medications until 21 May 2015.

resultsIn this review the mode of action, documented treatment effects and side effects of the approved MS therapies are briefly discussed.

conclusionsBased on current knowledge of risk-benefit of the approved MS medications, including factors influencing adherence, it is suggested that oral treatment with dimethyl fumarate or teriflunomide should be preferred as a starting therapy amongst the first-line preparations for de novo RRMS. In the case of breakthrough disease on first-line therapy, or rapidly evolving severe RRMS, second-line therapy with natalizumab, fingolimod or alemtuzumab should be chosen based on careful risk-benefit stratification.

Indexed as

Clinical Trials, Phase III as TopicRandomized Controlled Trials as TopicHumansImmunologic FactorsMultiple Sclerosis, Relapsing-RemittingImmunologic Factorsdisease-modifyingmultiple sclerosisreviewtreatment

Identifiers

PMID26563094
PMCPMC4670697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.